The U.S. Food and Drug Administration (FDA) has recently approved members of a new class of drugs specifically designed to treat migraine by targeting calcitonin gene-related peptide (CGRP), a substance that is elevated in blood serum during migraine attacks. Designed to decrease the number of migraine attacks, the new class of migraine drugs is metabolized differently and has fewer adverse reactions observed in clinical trials, as well as fewer warnings and precautions, compared to other approved migraine therapeutics.
For more information, please visit: Spotlight on CDER Science – New Drug Class Employs Novel Mechanism for Migraine Treatment and Prevention.
.png)
No hay comentarios:
Publicar un comentario